ACHILLES’ FOUNDERS MAP TRUNCAL AND BRANCHED MUTATIONS AND COPY NUMBER EVENTS TO PREDICT EARLY RELAPSE IN NON-SMALL CELL LUNG CANCER.

26/04/2017

Achilles Founders map truncal and branched mutations and copy number events to predict early relapse in non-small cell cancer lungs, opening up significant new opportunities for clinical trial design and monitoring of patients

A large scale Cancer Research UK study, TRACERx, which is led by the founders of Achilles, has found that unstable chromosomes within lung tumours increase the risk of cancer returning after surgery. The findings, which have been published in two prestigious medical research publications, the New England Journal of Medicine and Nature, reveal new insights into how tumours evolve and evade treatment, a leading cause of cancer death.

TRACERx, under lead researcher and Achilles founder Professor Charles Swanton, is the first study to look at the evolution of cancer in real time in immense detail. Researchers followed patients all the way from diagnosis through to either disease relapse or cure after surgery, tracking and analysing how their cancer developed.

Dr Chris Ashton, CEO of Achilles, said: “We continue to be excited by the value of what TRACERx is delivering and the impact this is having in helping Achilles develop new patient specific therapies that harness the immune system to destroy cancer cells. TRACERx is a unique resource which is enabling us to accelerate these potentially transformational therapies into the clinic.”

More information about the findings released in the research can be found here

AchillesLatest News

ACHILLES THERAPEUTICS RECEIVES CTA APPROVAL FOR PHASE I/II STUDY IN METASTIC OR RECURRENT MELANOMA – Second CTA approval in 2019 – the first was for a NSCLC study

13/02/2019

Stevenage, UK 13 February 2019 – Achilles Therapeutics (“Achilles”), a biopharmaceutical company developing personalised cancer immunotherapies, today announces the approval by...

Read More +

ACHILLES THERAPEUTICS APPOINTS DR MARKUS DANGL AS CHIEF SCIENTIFIC OFFICER

12/02/2019

Stevenage, UK 12 February 2019 – Achilles Therapeutics (“Achilles”), a biopharmaceutical company developing personalised cancer immunotherapies, today announces the appointment of...

Read More +

ACHILLES THERAPEUTICS RECEIVES CTA APPROVAL FOR PHASE I/II STUDY IN NON-SMALL CELL LUNG CANCER – Ground-breaking clinical trial in patients with significant unmet medical need to start this year

21/01/2019

Stevenage, UK 21 January 2019 – Achilles Therapeutics (“Achilles”), a biopharmaceutical company developing personalised cancer immunotherapies, today announces that its Clinical...

Read More +